Reliability of gene-expression profiling from tumor biopsy for refining neoadjuvant strategies in patients with head and neck squamous cell carcinoma
•Targeted gene-expression profiles of paired TB and SRS are highly correlated.•A perfect clustering of paired TB and SRS occurred in 52–64% of patients.•Immune-related pathways are stable across TB and SRS samples. While recent clinical trials evaluating neoadjuvant immune checkpoint inhibitors show...
Gespeichert in:
| Veröffentlicht in: | Oral oncology 2023-03, Vol.138, p.106310-106310, Article 106310 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106310 |
|---|---|
| container_issue | |
| container_start_page | 106310 |
| container_title | Oral oncology |
| container_volume | 138 |
| creator | Pellet, Adrien Bertolus, Chloé Saintigny, Pierre Foy, Jean-Philippe |
| description | •Targeted gene-expression profiles of paired TB and SRS are highly correlated.•A perfect clustering of paired TB and SRS occurred in 52–64% of patients.•Immune-related pathways are stable across TB and SRS samples.
While recent clinical trials evaluating neoadjuvant immune checkpoint inhibitors showed promising results in a subset of patients with head and neck squamous cell carcinomas (HNSCC), there is a need for the identification of robust biomarkers in tumor biopsies to improve patient selection. This context suggests unravelling transcriptomic heterogeneity between untreated paired samples from same patient with HNSCC. Based on previous studies and the analysis of publicly available gene expression profiles of paired tumor biopsies and surgical resection specimens, we discuss the reliability of tumor biopsy to capture the overall activation of targetable biological pathways in patients with HNSCC. Further studies investigating intratumor transcriptomic heterogeneity as well as the effect of sampling methods on gene expression are needed in patients with HNSCC, in order to develop innovative and relevant biomarker-driven neoadjuvant strategies. |
| doi_str_mv | 10.1016/j.oraloncology.2023.106310 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04459223v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1368837523000052</els_id><sourcerecordid>2770121226</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-c0a401fe03d70542b9ddef51192aeb03161a85ea4ada118f64182ad1ff9acbe93</originalsourceid><addsrcrecordid>eNqNUctu1DAUjRCIlsIvIIsVLDL4kSe7qjyKNBISgrV1Y1_PeEjsqe0MzIfwvzhKqViy8pXP49rnFMUrRjeMsubtYeMDjN4pP_rdecMpFxloBKOPikvWtX1J6148zrNourITbX1RPIvxQCmtWU2fFheiaSmnrLosfn_F0cJgR5vOxBuyQ4cl_joGjNF6R47Bmwy6HTHBTyTNkw9ksP4Yz8TkMaCxboEdetCH-QQukZgCJNxZjMRmC0gWXYrkp017skfQBJzOAvWDxLsZJj9HonAciYKgrPMTPC-eGBgjvrg_r4rvHz98u7ktt18-fb653paqon0qFYWKMoNU6JbWFR96rdHUjPUccKCCNQy6GqECDYx1pqlYx0EzY3pQA_biqniz-u5hlMdgJwhn6cHK2-utXO5oVdU95-LEMvf1ys2R3M0Yk5xsXJ4N-etzlLxtKeOM8yZT361UFXyMOaIHb0blUqE8yH8rlEuFcq0wi1_e75mHCfWD9G9nmfB-JWBO5mQxyKhywAq1DaiS1N7-z54_Smu30A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2770121226</pqid></control><display><type>article</type><title>Reliability of gene-expression profiling from tumor biopsy for refining neoadjuvant strategies in patients with head and neck squamous cell carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Pellet, Adrien ; Bertolus, Chloé ; Saintigny, Pierre ; Foy, Jean-Philippe</creator><creatorcontrib>Pellet, Adrien ; Bertolus, Chloé ; Saintigny, Pierre ; Foy, Jean-Philippe</creatorcontrib><description>•Targeted gene-expression profiles of paired TB and SRS are highly correlated.•A perfect clustering of paired TB and SRS occurred in 52–64% of patients.•Immune-related pathways are stable across TB and SRS samples.
While recent clinical trials evaluating neoadjuvant immune checkpoint inhibitors showed promising results in a subset of patients with head and neck squamous cell carcinomas (HNSCC), there is a need for the identification of robust biomarkers in tumor biopsies to improve patient selection. This context suggests unravelling transcriptomic heterogeneity between untreated paired samples from same patient with HNSCC. Based on previous studies and the analysis of publicly available gene expression profiles of paired tumor biopsies and surgical resection specimens, we discuss the reliability of tumor biopsy to capture the overall activation of targetable biological pathways in patients with HNSCC. Further studies investigating intratumor transcriptomic heterogeneity as well as the effect of sampling methods on gene expression are needed in patients with HNSCC, in order to develop innovative and relevant biomarker-driven neoadjuvant strategies.</description><identifier>ISSN: 1368-8375</identifier><identifier>EISSN: 1879-0593</identifier><identifier>DOI: 10.1016/j.oraloncology.2023.106310</identifier><identifier>PMID: 36702014</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biomarker ; Biopsy ; Cancer ; Carcinoma, Squamous Cell - pathology ; Gene expression ; Head and neck ; Head and Neck Neoplasms ; Humans ; Immune microenvironment ; Immunotherapy ; Life Sciences ; Neoadjuvant ; Neoadjuvant Therapy ; Oral cavity ; Reproducibility of Results ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck</subject><ispartof>Oral oncology, 2023-03, Vol.138, p.106310-106310, Article 106310</ispartof><rights>2023 Elsevier Ltd</rights><rights>Copyright © 2023 Elsevier Ltd. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c409t-c0a401fe03d70542b9ddef51192aeb03161a85ea4ada118f64182ad1ff9acbe93</cites><orcidid>0000-0002-8090-9323</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.oraloncology.2023.106310$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36702014$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04459223$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Pellet, Adrien</creatorcontrib><creatorcontrib>Bertolus, Chloé</creatorcontrib><creatorcontrib>Saintigny, Pierre</creatorcontrib><creatorcontrib>Foy, Jean-Philippe</creatorcontrib><title>Reliability of gene-expression profiling from tumor biopsy for refining neoadjuvant strategies in patients with head and neck squamous cell carcinoma</title><title>Oral oncology</title><addtitle>Oral Oncol</addtitle><description>•Targeted gene-expression profiles of paired TB and SRS are highly correlated.•A perfect clustering of paired TB and SRS occurred in 52–64% of patients.•Immune-related pathways are stable across TB and SRS samples.
While recent clinical trials evaluating neoadjuvant immune checkpoint inhibitors showed promising results in a subset of patients with head and neck squamous cell carcinomas (HNSCC), there is a need for the identification of robust biomarkers in tumor biopsies to improve patient selection. This context suggests unravelling transcriptomic heterogeneity between untreated paired samples from same patient with HNSCC. Based on previous studies and the analysis of publicly available gene expression profiles of paired tumor biopsies and surgical resection specimens, we discuss the reliability of tumor biopsy to capture the overall activation of targetable biological pathways in patients with HNSCC. Further studies investigating intratumor transcriptomic heterogeneity as well as the effect of sampling methods on gene expression are needed in patients with HNSCC, in order to develop innovative and relevant biomarker-driven neoadjuvant strategies.</description><subject>Biomarker</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Gene expression</subject><subject>Head and neck</subject><subject>Head and Neck Neoplasms</subject><subject>Humans</subject><subject>Immune microenvironment</subject><subject>Immunotherapy</subject><subject>Life Sciences</subject><subject>Neoadjuvant</subject><subject>Neoadjuvant Therapy</subject><subject>Oral cavity</subject><subject>Reproducibility of Results</subject><subject>Squamous cell carcinoma</subject><subject>Squamous Cell Carcinoma of Head and Neck</subject><issn>1368-8375</issn><issn>1879-0593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUctu1DAUjRCIlsIvIIsVLDL4kSe7qjyKNBISgrV1Y1_PeEjsqe0MzIfwvzhKqViy8pXP49rnFMUrRjeMsubtYeMDjN4pP_rdecMpFxloBKOPikvWtX1J6148zrNourITbX1RPIvxQCmtWU2fFheiaSmnrLosfn_F0cJgR5vOxBuyQ4cl_joGjNF6R47Bmwy6HTHBTyTNkw9ksP4Yz8TkMaCxboEdetCH-QQukZgCJNxZjMRmC0gWXYrkp017skfQBJzOAvWDxLsZJj9HonAciYKgrPMTPC-eGBgjvrg_r4rvHz98u7ktt18-fb653paqon0qFYWKMoNU6JbWFR96rdHUjPUccKCCNQy6GqECDYx1pqlYx0EzY3pQA_biqniz-u5hlMdgJwhn6cHK2-utXO5oVdU95-LEMvf1ys2R3M0Yk5xsXJ4N-etzlLxtKeOM8yZT361UFXyMOaIHb0blUqE8yH8rlEuFcq0wi1_e75mHCfWD9G9nmfB-JWBO5mQxyKhywAq1DaiS1N7-z54_Smu30A</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Pellet, Adrien</creator><creator>Bertolus, Chloé</creator><creator>Saintigny, Pierre</creator><creator>Foy, Jean-Philippe</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-8090-9323</orcidid></search><sort><creationdate>202303</creationdate><title>Reliability of gene-expression profiling from tumor biopsy for refining neoadjuvant strategies in patients with head and neck squamous cell carcinoma</title><author>Pellet, Adrien ; Bertolus, Chloé ; Saintigny, Pierre ; Foy, Jean-Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-c0a401fe03d70542b9ddef51192aeb03161a85ea4ada118f64182ad1ff9acbe93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarker</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Gene expression</topic><topic>Head and neck</topic><topic>Head and Neck Neoplasms</topic><topic>Humans</topic><topic>Immune microenvironment</topic><topic>Immunotherapy</topic><topic>Life Sciences</topic><topic>Neoadjuvant</topic><topic>Neoadjuvant Therapy</topic><topic>Oral cavity</topic><topic>Reproducibility of Results</topic><topic>Squamous cell carcinoma</topic><topic>Squamous Cell Carcinoma of Head and Neck</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pellet, Adrien</creatorcontrib><creatorcontrib>Bertolus, Chloé</creatorcontrib><creatorcontrib>Saintigny, Pierre</creatorcontrib><creatorcontrib>Foy, Jean-Philippe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Oral oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pellet, Adrien</au><au>Bertolus, Chloé</au><au>Saintigny, Pierre</au><au>Foy, Jean-Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reliability of gene-expression profiling from tumor biopsy for refining neoadjuvant strategies in patients with head and neck squamous cell carcinoma</atitle><jtitle>Oral oncology</jtitle><addtitle>Oral Oncol</addtitle><date>2023-03</date><risdate>2023</risdate><volume>138</volume><spage>106310</spage><epage>106310</epage><pages>106310-106310</pages><artnum>106310</artnum><issn>1368-8375</issn><eissn>1879-0593</eissn><abstract>•Targeted gene-expression profiles of paired TB and SRS are highly correlated.•A perfect clustering of paired TB and SRS occurred in 52–64% of patients.•Immune-related pathways are stable across TB and SRS samples.
While recent clinical trials evaluating neoadjuvant immune checkpoint inhibitors showed promising results in a subset of patients with head and neck squamous cell carcinomas (HNSCC), there is a need for the identification of robust biomarkers in tumor biopsies to improve patient selection. This context suggests unravelling transcriptomic heterogeneity between untreated paired samples from same patient with HNSCC. Based on previous studies and the analysis of publicly available gene expression profiles of paired tumor biopsies and surgical resection specimens, we discuss the reliability of tumor biopsy to capture the overall activation of targetable biological pathways in patients with HNSCC. Further studies investigating intratumor transcriptomic heterogeneity as well as the effect of sampling methods on gene expression are needed in patients with HNSCC, in order to develop innovative and relevant biomarker-driven neoadjuvant strategies.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36702014</pmid><doi>10.1016/j.oraloncology.2023.106310</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8090-9323</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-8375 |
| ispartof | Oral oncology, 2023-03, Vol.138, p.106310-106310, Article 106310 |
| issn | 1368-8375 1879-0593 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04459223v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Biomarker Biopsy Cancer Carcinoma, Squamous Cell - pathology Gene expression Head and neck Head and Neck Neoplasms Humans Immune microenvironment Immunotherapy Life Sciences Neoadjuvant Neoadjuvant Therapy Oral cavity Reproducibility of Results Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck |
| title | Reliability of gene-expression profiling from tumor biopsy for refining neoadjuvant strategies in patients with head and neck squamous cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T17%3A34%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reliability%20of%20gene-expression%20profiling%20from%20tumor%20biopsy%20for%20refining%20neoadjuvant%20strategies%20in%20patients%20with%20head%20and%20neck%20squamous%20cell%20carcinoma&rft.jtitle=Oral%20oncology&rft.au=Pellet,%20Adrien&rft.date=2023-03&rft.volume=138&rft.spage=106310&rft.epage=106310&rft.pages=106310-106310&rft.artnum=106310&rft.issn=1368-8375&rft.eissn=1879-0593&rft_id=info:doi/10.1016/j.oraloncology.2023.106310&rft_dat=%3Cproquest_hal_p%3E2770121226%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2770121226&rft_id=info:pmid/36702014&rft_els_id=S1368837523000052&rfr_iscdi=true |